中文

PacBio (PACB)

Healthcare

Close on Nov 11, 2026 (from our latest article): $2.09

Market value
$654Mat the Nov 11 close
Revenue growth
+4%12 months to Sep 30, 2026 (10-Q)
FCF margin
−89%12 months to Sep 30, 2026 (10-Q)
Net debt
$444Mat Sep 30, 2026
Worst fall since listing
−98.2%Feb 11, 2021 to May 27, 2025; not back to that high (−96.6% now)

About the company

Latest

  • Down 11.4% Explainer
    PacBio's cash runway meets a moving breakeven date

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

More of our coverage that names PacBio

Long-term fundamentals

Annual results for PacBio, FY2009–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $0.1M in FY2009 to $160M in FY2025. Free cash flow was positive in 1 of the 17 years shown; FY2025: −$114M. Each year's figures are in the table below. −$400M−$200M$0$200M$400M ’09 ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $0.1M in FY2009 to $160M in FY2025.

Free cash flow was positive in 1 of the 17 years shown; FY2025: −$114M.

Margins

Margins are not charted: in FY2025 the operating loss (−$554M) was larger than revenue ($160M). The table has each year's figures.

Diluted share count

The diluted share count rose 71% from FY2020 to FY2025, to 300M. Each year's figures are in the table below. 100M150M200M250M300M ’18’19’20’21’22’23’24’25

The diluted share count rose 71% from FY2020 to FY2025, to 300M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$160M29%−346%−$546M−$111M$3M−$114M
FY2024$154M24%−308%−$310M−$206M$6M−$212M
FY2023$201M26%−167%−$307M−$259M$9M−$268M
FY2022$128M38%−239%−$314M−$263M$17M−$280M
FY2021$131M45%−161%−$181M−$111M$6M−$117M
FY2020$79M41%−132%$29M$20M$1M$18M
FY2019$91M38%−111%−$84M−$78M$3M−$81M
FY2018$79M32%−128%−$103M−$66M$2M−$68M
FY2017$93M37%−96%−$92M−$68M$10M−$78M
FY2016$91M49%−79%−$74M−$68M$8M−$76M
FY2015$93M58%−31%−$32M−$48M$3M−$51M
FY2014$61M39%−104%−$66M−$51M$2M−$53M
FY2013$28M23%−275%−$79M−$30M$0.9M−$31M
FY2012$26M4%−363%−$94M−$77M$2M−$79M
FY2011$34M38%−324%−$109M−$103M$9M−$112M
FY2010$2M100%—−$140M−$122M$5M−$127M
FY2009$0.1M100%—−$88M−$75M$5M−$80M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025300M$280M$645M$42M——
FY2024288M$390M$647M$71M——
FY2023254M$727M$893M$72M——
FY2022225M$842M$899M$79M——
FY2021204M$1.2B$898M$73M——
FY2020175M$339M—$18M——
FY2019153M$49M$16M$16M——
FY2018135M$104M$15M$23M——
FY2017—$63M$14M$20M——
FY2016—$72M$16M$20M——
FY2015—$82M$15M$14M——
FY2014—$101M$14M$10M——
FY2013—$113M$13M$10M——
FY2012—$101M$3M$10M——
FY2011—$177M$3M$12M——
FY2010—$284M$3M$10M——
FY2009—$89M—$4M—$0.0M

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 11, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearPACBS&P 500
2019−30.5%+31.5%
2020+404.7%+18.4%
2021−21.1%+28.7%
2022−60.0%−18.1%
2023+19.9%+26.3%
2024−81.3%+25.0%
2025+2.2%+17.9%
2026 to date−5.9%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Healthcare

Questions about PacBio

Why did PacBio stock fall on Nov 12, 2026?
It isn't settled. At the last four quarters' average burn of $35.8 million, the $199.4 million PacBio had at Sep 30 would last into early 2028, the year it targets for breakeven, and the full $100 million stock program would add about two to three quarters (our calculation, not a forecast). PacBio expects burn to fall meaningfully in 2027; it has moved its breakeven date twice before. Read the article →